The estimated Net Worth of Diane Jorkasky is at least $126 mil dollars as of 27 June 2022. Diane Jorkasky owns over 17,610 units of Altimmune Inc stock worth over $126,264 and over the last 4 years he sold ALT stock worth over $0. In addition, he makes $0 as Director at Altimmune Inc.
Diane has made over 1 trades of the Altimmune Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 17,610 units of ALT stock worth $55,472 on 27 June 2022.
The largest trade he's ever made was exercising 17,610 units of Altimmune Inc stock on 27 June 2022 worth over $55,472. On average, Diane trades about 2,935 units every 0 days since 2020. As of 27 June 2022 he still owns at least 17,610 units of Altimmune Inc stock.
You can see the complete history of Diane Jorkasky stock trades at the bottom of the page.
Dr. Diane K. Jorkasky M.D. serves as Director of the Company. She has served on the board of directors of Alzheon, Inc., a private biopharmaceutical company, since December 2019 and also served on the board of directors of Q Therapeutics, Inc. from September 2013 until August 2016. From June 2014 to August 2019, she served as Executive Vice President, Chief Medical Officer and Head of Development at Complexa Inc., a clinical stated biopharmaceutical company. Dr. Jorkasky received her MD in 1977 from the University of Pennsylvania School of Medicine and is board certified in internal medicine, nephrology and clinical pharmacology. She is a member of the Connecticut Academy of Science and Technology. Dr. Jorkasky is on the faculties of University of California, San Francisco, and Uniformed Service of Health Sciences Medical Schools, with previous faculty appointments at Yale University and the University of Pennsylvania Schools of Medicine.
Diane Jorkasky is 68, he's been the Director of Altimmune Inc since 2020. There are 3 older and 9 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
Diane's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners..., eMitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: